These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 30776934)

  • 1. Effect of rifampicin-colistin combination against XDR Acinetobacter baumannii harbouring bla
    Ghaith D; Hassan R; Dawoud MEE; Eweis M; Metwally R; Zafer M
    Infect Dis (Lond); 2019 Apr; 51(4):308-311. PubMed ID: 30776934
    [No Abstract]   [Full Text] [Related]  

  • 2. Genomic analysis of in vivo acquired resistance to colistin and rifampicin in Acinetobacter baumannii.
    Jaidane N; Naas T; Mansour W; Radhia BB; Jerbi S; Boujaafar N; Bouallegue O; Bonnin RA
    Int J Antimicrob Agents; 2018 Feb; 51(2):266-269. PubMed ID: 29127051
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of Extensively Drug-Resistant blaOXA-23-Producing Acinetobacter baumannii Spread in a Greek Hospital.
    Mavroidi A; Katsiari M; Palla E; Likousi S; Roussou Z; Nikolaou C; Platsouka ED
    Microb Drug Resist; 2017 Jun; 23(4):488-493. PubMed ID: 27728770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phenotypic and molecular characterization of Acinetobacter baumannii isolates causing lower respiratory infections among ICU patients.
    Jain M; Sharma A; Sen MK; Rani V; Gaind R; Suri JC
    Microb Pathog; 2019 Mar; 128():75-81. PubMed ID: 30562602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In Vitro Interactions of Antibiotic Combinations of Colistin, Tigecycline, and Doripenem Against Extensively Drug-Resistant and Multidrug-Resistant Acinetobacter baumannii.
    Park GC; Choi JA; Jang SJ; Jeong SH; Kim CM; Choi IS; Kang SH; Park G; Moon DS
    Ann Lab Med; 2016 Mar; 36(2):124-30. PubMed ID: 26709259
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases.
    Tripodi MF; Durante-Mangoni E; Fortunato R; Utili R; Zarrilli R
    Int J Antimicrob Agents; 2007 Dec; 30(6):537-40. PubMed ID: 17851050
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequential emergence of colistin and rifampicin resistance in an OXA-72- producing outbreak strain of Acinetobacter baumannii.
    Potron A; Bour M; Triponney P; Muller J; Koebel C; A Bonnin R; Plésiat P
    Int J Antimicrob Agents; 2019 May; 53(5):669-673. PubMed ID: 30685310
    [TBL] [Abstract][Full Text] [Related]  

  • 8. In vitro activities of carbapenem/sulbactam combination, colistin, colistin/rifampicin combination and tigecycline against carbapenem-resistant Acinetobacter baumannii.
    Song JY; Kee SY; Hwang IS; Seo YB; Jeong HW; Kim WJ; Cheong HJ
    J Antimicrob Chemother; 2007 Aug; 60(2):317-22. PubMed ID: 17540672
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Soudeiha MAH; Dahdouh EA; Azar E; Sarkis DK; Daoud Z
    Front Cell Infect Microbiol; 2017; 7():209. PubMed ID: 28596943
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic characterization of extensively drug-resistant Acinetobacter baumannii strain, KAB03 belonging to ST451 from Korea.
    Lee SY; Oh MH; Yun SH; Choi CW; Park EC; Song HS; Lee H; Yi YS; Shin J; Chung C; Moon JY; Lee JC; Kim GH; Kim SI
    Infect Genet Evol; 2018 Nov; 65():150-158. PubMed ID: 30053642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro antimicrobial synergy of colistin with rifampicin and carbapenems against colistin-resistant Acinetobacter baumannii clinical isolates.
    Hong DJ; Kim JO; Lee H; Yoon EJ; Jeong SH; Yong D; Lee K
    Diagn Microbiol Infect Dis; 2016 Oct; 86(2):184-9. PubMed ID: 27475960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. High prevalence of OXA-type carbapenemases among Acinetobacter baumannii strains in a teaching hospital of Tehran.
    Zafari M; Feizabadi MM; Jafari S; Abdollahi A; Sabokbar A
    Acta Microbiol Immunol Hung; 2017 Dec; 64(4):385-394. PubMed ID: 28870091
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carbapenemase-producing Acinetobacter baumannii, Algeria.
    Drissi M; Poirel L; Mugnier PD; Baba Ahmed Z; Nordmann P
    Eur J Clin Microbiol Infect Dis; 2010 Nov; 29(11):1457-8. PubMed ID: 20632052
    [No Abstract]   [Full Text] [Related]  

  • 14. In vivo activity of co-trimoxazole combined with colistin against Acinetobacter baumannii producing OXA-23 in a Galleria mellonella model.
    Khalil MAF; Moawad SS; Hefzy EM
    J Med Microbiol; 2019 Jan; 68(1):52-59. PubMed ID: 30422109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular Epidemiology of Carbapenem-Resistant Acinetobacter baumannii in a Tertiary Care Hospital in Egypt: Clonal Spread of blaOXA-23.
    El Bannah AMS; Nawar NN; Hassan RMM; Salem STB
    Microb Drug Resist; 2018 Apr; 24(3):269-277. PubMed ID: 28783427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Song JY; Lee J; Heo JY; Noh JY; Kim WJ; Cheong HJ; Hwang IS
    Int J Antimicrob Agents; 2008 Sep; 32(3):281-4. PubMed ID: 18650070
    [No Abstract]   [Full Text] [Related]  

  • 17. Coexistence of blaOXA-23 with armA in quinolone-resistant Acinetobacter baumannii from a Chinese university hospital.
    Shen M; Luan G; Wang Y; Chang Y; Zhang C; Yang J; Deng S; Ling B; Jia X
    Diagn Microbiol Infect Dis; 2016 Mar; 84(3):230-1. PubMed ID: 26740313
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular Characterization of Carbapenem-Resistant Acinetobacter baumannii in the Intensive Care Unit of Uruguay's University Hospital Identifies the First rmtC Gene in the Species.
    Bado I; Papa-Ezdra R; Delgado-Blas JF; Gaudio M; Gutiérrez C; Cordeiro NF; García-Fulgueiras V; Araújo Pirez L; Seija V; Medina JC; Rieppi G; Gonzalez-Zorn B; Vignoli R
    Microb Drug Resist; 2018 Sep; 24(7):1012-1019. PubMed ID: 29920143
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lipopolysaccharide loss produces partial colistin dependence and collateral sensitivity to azithromycin, rifampicin and vancomycin in Acinetobacter baumannii.
    García-Quintanilla M; Carretero-Ledesma M; Moreno-Martínez P; Martín-Peña R; Pachón J; McConnell MJ
    Int J Antimicrob Agents; 2015 Dec; 46(6):696-702. PubMed ID: 26391380
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of carbapenem-resistant Acinetobacter baumannii ST787 in clinical isolates from blood in a tertiary teaching hospital in Northern Taiwan.
    Hu YF; Hou CJ; Kuo CF; Wang NY; Wu AY; Leung CH; Liu CP; Yeh HI
    J Microbiol Immunol Infect; 2017 Oct; 50(5):640-645. PubMed ID: 28711441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.